Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2012

View Archived Issues

TMX-202 shows potential as intravesically administered bladder cancer therapy

Orteronel investigated in nonmetastatic prostate cancer

Updated results presented from the AXIS trial

New VCP inhibitors designed in Japan

Novel metabotropic glutamate mGlu2 receptor antagonists patented

Prous Institute for Biomedical Research reports new multitargeted products

Eli Lilly presents novel products with potential to treat cancer

New 11-beta-HSD1 inhibitors developed at High Point Pharmaceuticals

Auriga identifies novel potential therapeutics for photodermatosis

Selective serotonin transporter radioligand investigated in healthy subjects and patients

Sirona Biochem assesses lead product in model of diabetes

Novartis seeks Afinitor line extensions in Japan

EMA accepts Takeda's MAA for peginesatide

Angiochem and GSK launch new collaboration

Eisai offers overview of third quarter of fiscal 2011

Neuronex enters merger agreement

CSL Behring screens first patient in global rVIII-SingleChain study

European Commission approves Glivec label update

Chinese institute divulges new beta-secretase 1 inhibitors

Esmya approved in Europe

Scripps Research Institute receives funds to develop new HIV inhibitors

Sanofi discloses new platelet adhesion-inhibiting peptides

Galen acquires chemotherapy agent from Gilead

FDA approves protocol amendment to ARISER study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.